ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0915

Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis

Helena Port Linares1, Signe Holm Nielsen2, Peder Frederiksen3, Sofie Falkenløve Madsen4, Anne-Christine Bay-Jensen5, Morten Karsdal5, Inge Juul Sørensen6, Bente Jensen7, Anne Gitte Loft8, Ole Rintek Madsen7, Mikkel Ostergaard9 and Susanne Pedersen10, 1Nordic Bioscience and University of Copenhagen, School of Health and Medical Sciences, Copenhagen, Denmark, 2Nordic Bioscience and Technical University of Denmark, Biomedicine and Biotechnology, Kgs. Lyngby, Herlev, Denmark, 3Nordic Bioscience, Herlev, Copenhagen, Denmark, 4University of Copenhagen, School of Health and Medical Sciences, Herlev, Copenhagen, Denmark, 5Nordic Bioscience, Herlev, Denmark, 6Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 7Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 8Aarhus University Hospital, Aarhus, Denmark, 9Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 10Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease associated with extracellular matrix (ECM) remodeling of the cartilage, bone, and connective tissues. Quantification of ECM-mediated biomarkers may be useful to determine treatment response in axSpA. The aim of this study was to identify biomarkers reflecting the pharmacodynamic effect and the treatment response of adalimumab in two placebo-controlled axSpA studies.

Methods: Biomarkers reflecting the degradation of collagen type I (C1M), II (C2M and T2CM), III (C3M), IV (C4M), VI (C6M), formation of collagen type II (PRO-C2), III (PRO-C3), IV (PRO-C4) and VI (PRO-C6) and inflammation (CRPM, PROM, and VICM) were measured in serum from the ASIM study (n=45) and the DANISH study (n=49) at baseline, week 6 or 12 (ASIM and DANISH, respectively), and week 24. Patients received treatment with adalimumab 40 mg or placebo the first 6 or 12 weeks (ASIM and DANISH, respectively) followed by adalimumab 40 mg for an additional 18 or 12 weeks (ASIM and DANISH, respectively). Differences in fold change of biomarker levels between week 6 or week 12 (ASIM and DANISH, respectively) and baseline were evaluated by a linear regression model to investigate treatment pharmacodynamics. A linear regression model adjusted by treatment (active treatment or placebo for the first 6 or 12 weeks, ASIM and DANISH, respectively) were applied to investigate treatment response. Response to treatment was evaluated as a reduction of at least 50% in BASDAI index from baseline to week 24.

Results: In the ASIM vs. DANISH study 56% vs. 78% of the patients were male, the mean (SD) age of the patients was 37.6 (9.9) vs. 39.5 (11.2) and frequency of HLA-B27 78% vs. 88%. The 22 patients representing the primarily actively treated group in the ASIM study presented significantly lower fold change in C1M, C3M, C4M, C6M, and PRO-C4 over the first 6 weeks as compared to the placebo group (p< 0.001, p< 0.001, p< 0.001, p< 0.001, p= 0.018, respectively Table 1), and showed a significantly higher fold change in the ratios of formation/degradation of collagen type III, IV and VI (all p< 0.001). The 24 patients from the actively treated group in the DANISH study had a significantly lower fold change over the first 12 weeks in C1M, C3M, C4M, C6M as compared to the placebo group (p=0.002, p=0.02, p=0.015, p=0.011, respectively, Table 1), and had a significantly higher fold change in the ratios of formation/degradation of collagen type IV and VI (p=0.009, p=0.049, respectively). Thirty-two out of 45 patients were considered responders in the ASIM study, and 43 out of 46 patients in the DANISH study (Table 2). In the ASIM study, levels of PRO-C4 presented a significantly lower fold change in responders compared to non-responders (p=0.042), while in the DANISH study, levels of C3M and C4M had both a significantly lower fold change in responders compared to non-responders (both p=0.04, Table 2).

Conclusion: The biomarkers C1M, C3M, C4M, and C6M may have potential as pharmacodynamic biomarkers, while the biomarkers C3M and C4M were associated with response to adalimumab treatment after 24 weeks.


Disclosures: H. Port Linares, None; S. Nielsen, Nordic Bioscience, 3; P. Frederiksen, None; S. Falkenløve Madsen, None; A. Bay-Jensen, Nordic Biosciences, 3, 11; M. Karsdal, Nordic Biosciences, 3, 11; I. Sørensen, None; B. Jensen, None; A. Gitte Loft, None; O. Rintek Madsen, None; M. Ostergaard, AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Celgene, 2, 6, Novartis, 2, 5, 6, Boehringer Ingelheim, 2, 6, Eli Lilly, 2, 6, Hospira, 2, 6, Janssen, 2, 6, Merck, 2, 5, 6, Novo, 2, 6, Orion, 2, 6, Pfizer Inc, 2, 6, Regeneron, 2, 6, Roche, 2, 6, UCB, 2, 6, GSK, 2, 6, Mundipharma, 2, 6, Schering-Plough, 2, 6, Takeda, 2, 6, Wyeth, 2, 6, Centocor, 2, 5, 6; S. Pedersen, None.

To cite this abstract in AMA style:

Port Linares H, Nielsen S, Frederiksen P, Falkenløve Madsen S, Bay-Jensen A, Karsdal M, Sørensen I, Jensen B, Gitte Loft A, Rintek Madsen O, Ostergaard M, Pedersen S. Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/biomarkers-of-extracellular-matrix-turnover-reflect-treatment-response-and-pharmacodynamic-effects-of-tnf-%ce%b1-inhibitory-therapy-in-patients-with-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-of-extracellular-matrix-turnover-reflect-treatment-response-and-pharmacodynamic-effects-of-tnf-%ce%b1-inhibitory-therapy-in-patients-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology